結紮市場 - 全球產業規模、佔有率、趨勢、機會和預測：按類型、患者、最終用戶、地區和競爭格局分類，2021-2031 年

全球切除術市場預計將從 2025 年的 231.1 億美元成長到 2031 年的 362.1 億美元，複合年成長率為 7.77%。

切除術是一種男性節育手術手術，透過阻斷輸精管，阻止精子進入精液，達到永久避孕的目的。市場成長的主要促進因素是其與女性節育手術相比更具成本效益，以及微創、無刀手術方式日益普及，從而縮短了恢復時間。這種日益成長的接受度也體現在實施數據中；根據英國國家醫療服務體系（NHS）英格蘭數位部門的數據，2024會計年度英格蘭性與生殖健康服務機構共進行了22,775例切除術，顯示市場需求旺盛。

儘管存在這些有利條件，但根深蒂固的文化偏見以及與男性氣質和性能力相關的心理擔憂阻礙了市場成長。手術的永久性使潛在患者猶豫不決，他們擔心未來會後悔以及生理上的變化。因此，缺乏有效的教育措施來消除這些誤解，阻礙了市場的進一步滲透，尤其是在保守地區，人們對手術的安全性和具體情況了解不足。

市場促進因素

市場成長的主要催化劑是人們不再僅僅將避孕視為女性的責任，以及男性在計劃生育中積極參與的意識日益增強。這一趨勢的特徵是顯著的人口結構變化，越來越多的年輕男性選擇接受節育手術，這主要受生殖權利環境變化和共同責任意識增強的推動。美國泌尿系統協會2024年年會的數據凸顯了這一轉變，報告顯示，在美國法律改革後，30歲以下切除術的男性比例上升至9.8%。目標族群的擴大降低了市場對已完成計劃生育的老年男性的依賴。

同時，政府計畫和非政府組織為改善永久避孕手術的可近性而進行的努力，推動了人們對永久避孕的需求。這些組織在克服費用障礙、透過補貼和宣傳活動普及手術方面發揮著至關重要的作用，有效地將人們的興趣轉化為實際的治療。英國國家醫療服務體系（NHS）英格蘭分部2024年9月發布的數位報告清晰地反映了這一需求的規模，該報告顯示，切除術手術的數量較前一年激增了113%。此外，美國計劃生育聯合會2024年為5,388名患者實施了切除術，凸顯了便利的醫療服務提供者在滿足全球日益成長的男性節育手術需求方面發揮的重要作用。

市場挑戰

市場成長很大程度上受到根深蒂固的文化偏見和關於男性氣質和性能力的心理障礙的阻礙。這些潛在的誤解，加上手術的不可逆性，導致許多男性猶豫不決，他們害怕後悔和身體上的變化。一種普遍但毫無根據的觀念將生育能力等同於男性氣質，使得許多男性將切除術視為一種閹割或性功能衰退。這種心理抵觸是一個主要障礙，尤其是在男性在生育決策中佔據主導地位的保守社會中，這種主導地位已根深蒂固。

儘管輸精管結紮術的臨床成功率很高，但這些顧慮仍阻礙了其廣泛應用。英國泌尿系統協會（BAUS）2024年的數據顯示，公眾認知與醫學現實之間存在顯著差距。數據顯示，術後延遲失敗率僅兩千分之一，慢性疼痛的發生率也僅1-2%。然而，關於失敗和副作用的普遍誤解掩蓋了這些積極的統計數據，導致全球切除術的普及率遠低於女性節育手術手術。

市場趨勢

生技公司正積極推動非荷爾蒙聚合物基封閉劑的商業化，旨在開闢一個新的市場領域：可逆性男性節育手術。這項創新技術克服了永久性絕育帶來的心理障礙，並透過使用可注射水凝膠阻斷精子流動而不切斷輸精管，為傳統的結紮術提供了一種靈活的替代方案。該領域的進展迅速。根據 Femtech Insider 2025 年 4 月報道，「ADAM」水凝膠系統在美國泌尿系統協會 (AUA) 年會上取得了重大進展，初步試驗結果顯示，兩名受試者在 24 個月內保持了安全性和無精子症狀態。

同時，數位化健康措施正在推動文化轉型，消除歷史遺留的偏見，並將切除術重新定義為負責任的生活方式選擇。社群媒體上的意見領袖和患者的親身經歷提高了人們對這項手術的認知度，並加速了那些先前對尋求生殖醫療服務猶豫不決的人群的需求。人口連結組織（Population Connection）2025年3月發布的報告指出，這種偏見的消除正在推動顯著成長，公共意識的提高加速了臨床需求。一項研究指出，為了因應不斷變化的生殖環境，選擇輸精管結紮術的年​​輕男性比例比以往的基準值水準提高了95%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球結紮市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型（傳統手術、微創手術、無需手術刀）
  • 按患者（動物、人類）
  • 依最終使用者（醫院/診所、門診中心、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美結紮市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲結紮市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區結紮市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲結紮技術市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲結紮技術市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球結紮市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Pfizer Inc
• Bristol Myers Squibb SA
• Teva Pharmaceuticals USA Inc
• Upsher-Smith Laboratories Inc
• SMITHFIELD BIOSCIENCE
• Opocrin SPA
• Bioiberica SA
• GSK PLC
• Johnson & Johnson Consumer Inc
• Fresenius SE & Co KGaA

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Vasectomy Market is projected to expand from USD 23.11 Billion in 2025 to USD 36.21 Billion by 2031, registering a CAGR of 7.77%. Vasectomy is defined as a surgical method for male sterilization that ensures permanent contraception by blocking the vas deferens to prevent sperm from entering the seminal fluid. Market growth is largely driven by the procedure's cost-effectiveness compared to female sterilization and the rising adoption of minimally invasive no-scalpel techniques, which offer reduced recovery times. This increasing acceptance is reflected in operational data; according to NHS England Digital, the 2024 fiscal year saw Sexual and Reproductive Health services in England perform 22,775 vasectomy procedures, indicating a strong uptake.

Despite these favorable conditions, market growth is hampered by enduring cultural stigmas and psychological concerns related to masculinity and sexual potency. The permanent nature of the surgery instills hesitation in potential patients who fear future regret or physiological changes. Consequently, a lack of effective educational initiatives to debunk these myths restricts deeper market penetration, especially in conservative regions where knowledge regarding the safety and specific nature of the procedure remains inadequate.

Market Driver

A primary catalyst for market growth is the increasing involvement of men in family planning, which marks a shift from contraception being viewed solely as a female responsibility. This trend is defined by a significant demographic expansion, with younger men increasingly choosing sterilization due to the evolving reproductive rights landscape and a desire for shared accountability. Data from the American Urological Association's 2024 Annual Meeting highlights this shift, reporting that following legal changes in the United States, the percentage of vasectomy patients under 30 rose to 9.8%. This broadening demographic reduces the market's historical dependence on older men who have already completed their families.

Concurrently, demand for permanent contraception is being boosted by government programs and NGO efforts aimed at improving procedure accessibility. These organizations play a vital role in overcoming cost barriers and normalizing the surgery through subsidies and education, effectively turning interest into actual procedures. The magnitude of this demand is evident in the NHS England Digital report from September 2024, which recorded a dramatic 113% year-on-year increase in vasectomy procedures. Additionally, the Planned Parenthood Federation of America served 5,388 vasectomy clients in 2024, underscoring the essential role of accessible providers in meeting the rising global demand for male sterilization.

Market Challenge

Market growth is significantly obstructed by persistent cultural stigmas and psychological barriers concerning masculinity and sexual potency. These deep-rooted misconceptions, combined with the finality of the procedure, generate considerable hesitation among men who fear regret or physiological alterations. A common but unfounded belief equates fertility with virility, leading many to view vasectomy as a form of castration or a cause of diminished sexual performance. This psychological resistance acts as a major restraint, particularly in conservative societies where male dominance in reproductive decision-making is culturally ingrained.

Although the procedure has a high clinical success rate, these fears continue to limit its widespread adoption. There is a marked discrepancy between public perception and medical reality, as highlighted by 2024 data from the British Association of Urological Surgeons, which reported a late procedural failure rate of only 1 in 2,000 and chronic pain affecting just 1-2% of patients. However, the prevalence of myths regarding failure and side effects obscures these favorable statistics, causing global vasectomy uptake to lag significantly behind that of female sterilization methods.

Market Trends

Biotechnology companies are actively pursuing the commercialization of non-hormonal, polymer-based occlusives to create a new market segment for reversible male sterilization. This innovation tackles the psychological barrier of permanence by using injectable hydrogels that block sperm flow without severing the vas deferens, providing a flexible alternative to traditional ligation. Progress in this area is rapid; according to Femtech Insider in April 2025, the 'ADAM' hydrogel system achieved a key milestone at the American Urological Association meeting, where early trial results showed two participants maintained safety and azoospermia at the 24-month mark.

Simultaneously, digital health advocacy is driving a cultural shift that is dismantling historical stigmas and rebranding vasectomy as a responsible lifestyle choice. Social media influencers and patient testimonials are normalizing the procedure, thereby accelerating demand among groups previously hesitant to seek reproductive health services. This destigmatization is fueling measurable growth; according to Population Connection in March 2025, increased public interest has compounded clinical demand, with a study noting that young men are utilizing vasectomy services at a rate 95% higher than previous baselines in response to the changing reproductive landscape.

Key Market Players

• Pfizer Inc
• Bristol Myers Squibb SA
• Teva Pharmaceuticals USA Inc
• Upsher-Smith Laboratories Inc
• SMITHFIELD BIOSCIENCE
• Opocrin SPA
• Bioiberica SA
• GSK PLC
• Johnson & Johnson Consumer Inc
• Fresenius SE & Co KGaA

Report Scope

In this report, the Global Vasectomy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Vasectomy Market, By Type

• Conventional
• Minimally Invasive
• No-Scalpel

Vasectomy Market, By Patient

• Animal
• Human

Vasectomy Market, By End-User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Vasectomy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Vasectomy Market.

Available Customizations:

Global Vasectomy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Vasectomy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Conventional, Minimally Invasive, No-Scalpel)
  • 5.2.2. By Patient (Animal, Human)
  • 5.2.3. By End-User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Vasectomy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Patient
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Vasectomy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Patient
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Vasectomy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Patient
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Vasectomy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Patient
      • 6.3.3.2.3. By End-User

7. Europe Vasectomy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Patient
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Vasectomy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Patient
      • 7.3.1.2.3. By End-User
  • 7.3.2. France Vasectomy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Patient
      • 7.3.2.2.3. By End-User
  • 7.3.3. United Kingdom Vasectomy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Patient
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Vasectomy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Patient
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Vasectomy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Patient
      • 7.3.5.2.3. By End-User

8. Asia Pacific Vasectomy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Patient
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Vasectomy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Patient
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Vasectomy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Patient
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan Vasectomy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Patient
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea Vasectomy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Patient
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Vasectomy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Patient
      • 8.3.5.2.3. By End-User

9. Middle East & Africa Vasectomy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Patient
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Vasectomy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Patient
      • 9.3.1.2.3. By End-User
  • 9.3.2. UAE Vasectomy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Patient
      • 9.3.2.2.3. By End-User
  • 9.3.3. South Africa Vasectomy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Patient
      • 9.3.3.2.3. By End-User

10. South America Vasectomy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Patient
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Vasectomy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Patient
      • 10.3.1.2.3. By End-User
  • 10.3.2. Colombia Vasectomy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Patient
      • 10.3.2.2.3. By End-User
  • 10.3.3. Argentina Vasectomy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Patient
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Vasectomy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bristol Myers Squibb SA
• 15.3. Teva Pharmaceuticals USA Inc
• 15.4. Upsher-Smith Laboratories Inc
• 15.5. SMITHFIELD BIOSCIENCE
• 15.6. Opocrin SPA
• 15.7. Bioiberica SA
• 15.8. GSK PLC
• 15.9. Johnson & Johnson Consumer Inc
• 15.10. Fresenius SE & Co KGaA

16. Strategic Recommendations

17. About Us & Disclaimer